Lantern Pharma Inc (LTRN)

Sep 19, 2026

New to The Street will broadcast interviews with executives from BioVie, Acurx Pharmaceuticals, Lantern Pharma, and SafeSpace Global tonight at 6:30 PM ET. The program, distributed across the US, Latin America, and MENA, will cover topics including Long COVID treatments, new antibiotics, AI in oncology drug development, and AI-powered security platforms. The co-founder and CEO of New to The Street, Vince Caruso, highlighted the platform's reach for innovative companies to communicate with investors and the public.

Sep 19, 2026

New to The Street is broadcasting interviews tonight at 6:30 PM ET featuring executives from BioVie, Acurx Pharmaceuticals, Lantern Pharma, and SafeSpace Global. The program will cover topics including Long COVID clinical results, new antibiotic development, AI in oncology research, and AI-powered security platforms. It will air across Bloomberg Television's U.S., Latin America, and MENA markets.

Sep 19, 2026

Lantern Pharma reported significant progress in its AI-driven drug development, highlighted by the establishment of Open Medicine AI as a separate entity to commercialize its AI models. The company achieved a 25% reduction in operating expenses year-over-year while advancing multiple clinical programs, including promising results for LP300 in non-small cell lung cancer and regulatory clearances for LP184 trials. Open Medicine AI, wholly owned by Lantern Pharma, aims to raise independent capital and pursue a separate listing, leveraging the growing AI market in drug discovery.